{
  "title": "Leucemia Neutrofílica Crónica (LNC) y Leucemia Mieloide Crónica Atípica (LMCa): Actualización **2024** sobre Diagnóstico, Genética, Estratificación de Riesgo y Manejo (**Szuber N, Orazi A, Tefferi A**)",
  "guid": "5A93332021E270C338F7F223",
  "filepath": "/sessions/bold-jolly-cerf/mnt/Dropbox/- Esquemas/- Entidades clínicas/Hematología/Paper. Leucemia Neutrofílica Crónica y Leucemia Mieloide Cronica Atípica-2025-1.smmx",
  "root": {
    "id": "0",
    "parent": "-1",
    "text": "Leucemia Neutrofílica Crónica (LNC) y Leucemia Mieloide\nCrónica Atípica (LMCa): Actualización **2024** sobre\nDiagnóstico, Genética, Estratificación de Riesgo y Manejo\n(**Szuber N, Orazi A, Tefferi A**)",
    "guid": "SMdTmV8JAxkmzcEsK4qkNQ",
    "children": [
      {
        "id": "1",
        "parent": "0",
        "text": "- Leucemia\nNeutrofílica Crónica\n(LNC)",
        "guid": "",
        "children": [
          {
            "id": "2",
            "parent": "1",
            "text": "› Definición",
            "guid": "f7kUPFtKByw0sZwkWHEbMA",
            "children": [
              {
                "id": "3",
                "parent": "2",
                "text": "◊ Neoplasia mieloproliferativa (NMP) rara, BCR::ABL1 negativa",
                "guid": "YLIE3la_X0AM6lQeTMz0cg",
                "children": []
              },
              {
                "id": "4",
                "parent": "2",
                "text": "◊ ★ Leucocitosis neutrofílica madura persistente",
                "guid": "a7f0GBqeN4RyEhVqHbA0YQ",
                "children": []
              },
              {
                "id": "5",
                "parent": "2",
                "text": "◊ Hiperplasia granulocítica en médula ósea (MO)",
                "guid": "JzoeVRJIZNVymlbpDWxpsA",
                "children": []
              }
            ]
          },
          {
            "id": "6",
            "parent": "1",
            "text": "› Historia",
            "guid": "e9rZWRyArCpYk4pZFA4VoA",
            "children": [
              {
                "id": "7",
                "parent": "6",
                "text": "◊ **Tuohy (1920)**: Primeros reportes",
                "guid": "dxPfS3p1-xxNBgfDP9sy5A",
                "children": []
              },
              {
                "id": "8",
                "parent": "6",
                "text": "◊ **Tanzer et al. (1964)**: Término \"LNC\"",
                "guid": "WX7-NXPTyO9rZdcZMKEtYg",
                "children": []
              },
              {
                "id": "9",
                "parent": "6",
                "text": "◊ **OMS (2001)**: Entidad clínica distinta",
                "guid": "MSuKNFCk3lNE1JR2MOSecQ",
                "children": []
              }
            ]
          },
          {
            "id": "10",
            "parent": "1",
            "text": "› Epidemiología",
            "guid": "K-7lf3mGMJoJVbmhDKDqXQ",
            "children": [
              {
                "id": "11",
                "parent": "10",
                "text": "◊ Incidencia rara (**SEER**: 0.1/1,000,000)",
                "guid": "UEWP2xZADcBZbd7QO_2D8w",
                "children": []
              },
              {
                "id": "12",
                "parent": "10",
                "text": "◊ Edad media: 71 años (rango 33-92.5)",
                "guid": "MN5FREt_9DpZrbhUWBhjmQ",
                "children": []
              },
              {
                "id": "13",
                "parent": "10",
                "text": "◊ Ligera preponderancia masculina (56-62.5%)",
                "guid": "XchZD0xIDz1lhM1KWaMyaA",
                "children": []
              }
            ]
          },
          {
            "id": "14",
            "parent": "1",
            "text": "› Características\nClínicas",
            "guid": "aMi7aD4YV6NtsUgIX9yasw",
            "children": [
              {
                "id": "15",
                "parent": "14",
                "text": "◊ Heterogénea, a menudo hallazgo incidental (leucocitosis)",
                "guid": "OI5Svzq3T8sft82XEg1Q9A",
                "children": []
              },
              {
                "id": "16",
                "parent": "14",
                "text": "◊ Síntomas: Constitucionales, fatiga, dolor óseo, prurito, hematomas fáciles, gota",
                "guid": "LosYuwsdpLBCrn5XX7ai7w",
                "children": []
              },
              {
                "id": "17",
                "parent": "14",
                "text": "◊ Signos: ★ Esplenomegalia (~67%), Hepatomegalia. Rara afectación ganglionar.",
                "guid": "W8KDAweDEs0Qm0FgB7Fogg",
                "children": []
              },
              {
                "id": "18",
                "parent": "14",
                "text": "◊ Complicaciones: ★ Diátesis hemorrágica\n(mucocutánea, GI, cerebral)",
                "guid": "AQlDaBnw-wIUUlLgUU7TQw",
                "children": [
                  {
                    "id": "19",
                    "parent": "18",
                    "text": "• Atribuida a trombocitopenia, disfunción plaquetaria, infiltración vascular",
                    "guid": "MDEIwm3AMbANTFc2YQ9OBg",
                    "children": []
                  },
                  {
                    "id": "20",
                    "parent": "18",
                    "text": "• Investigar: Enfermedad de von Willebrand adquirida, trastornos coagulación/función plaquetaria",
                    "guid": "OUAl6mb6D4s5J7GgFwh--Q",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "21",
            "parent": "1",
            "text": "› Hallazgos de\nLaboratorio",
            "guid": "M0IeyB6sfupwq7FhHAraMA",
            "children": [
              {
                "id": "22",
                "parent": "21",
                "text": "◊ ★ Neutrofilia madura persistente (≥80% segmentados/bandas)",
                "guid": "XMTWjV5c-Wp753TjFVMpTA",
                "children": []
              },
              {
                "id": "23",
                "parent": "21",
                "text": "◊ <10% precursores mieloides circulantes (promielocitos, mielocitos, metamielocitos)",
                "guid": "GRRJNRufQnonYHpAR59h8A",
                "children": []
              },
              {
                "id": "24",
                "parent": "21",
                "text": "◊ Raros mieloblastos",
                "guid": "JrznKmoO-JcnVgTgAn9qLQ",
                "children": []
              },
              {
                "id": "25",
                "parent": "21",
                "text": "◊ Ausencia de monocitosis (<10%), basofilia, eosinofilia",
                "guid": "cZILZTfxRkAKMNKwcptOzQ",
                "children": []
              },
              {
                "id": "26",
                "parent": "21",
                "text": "◊ Anemia leve/moderada (Hb media ~7.9-11 g/dL)",
                "guid": "UeJBQh6DJZBD6iIQAhNKBA",
                "children": []
              },
              {
                "id": "27",
                "parent": "21",
                "text": "◊ Trombocitopenia (menos común, Plaquetas medias ~260x10⁹/L)",
                "guid": "DENXQFE2eUZjIpgLRYN9Kg",
                "children": []
              },
              {
                "id": "28",
                "parent": "21",
                "text": "◊ LDH elevada",
                "guid": "ODCI0RxKSatci_wja3Knmg",
                "children": []
              },
              {
                "id": "29",
                "parent": "21",
                "text": "◊ ★ Fosfatasa alcalina leucocitaria (FAL) alta (vs. baja en LMC)",
                "guid": "OvbIlU03rYQHfYHKF7ufIg",
                "children": []
              },
              {
                "id": "30",
                "parent": "21",
                "text": "◊ Vitamina B12 elevada (liberación transcobalamina)",
                "guid": "K5Sm7gNk9q4tDshuRKjwJA",
                "children": []
              },
              {
                "id": "31",
                "parent": "21",
                "text": "◊ G-CSF sérico bajo (no rutinario)",
                "guid": "HwQ5KFRvQq4MSFIURcEgUw",
                "children": []
              },
              {
                "id": "32",
                "parent": "21",
                "text": "◊ Empeoramiento anemia/trombocitopenia, ↑leucocitosis/esplenomegalia → Progresión/Crisis blástica",
                "guid": "Pn47RjOeVvRIQIqAMBBGqw",
                "children": []
              }
            ]
          },
          {
            "id": "33",
            "parent": "1",
            "text": "› Morfología\nMédula Ósea",
            "guid": "a4-dNVJxXTAiq5V4PXHedw",
            "children": [
              {
                "id": "34",
                "parent": "33",
                "text": "◊ ★ Hipercelular (>90%)",
                "guid": "cPSCwGaVt4g_hSh8fTfaAA",
                "children": []
              },
              {
                "id": "35",
                "parent": "33",
                "text": "◊ ↑ Granulopoyesis neutrofílica (Ratio M:E >20:1), maduración predominantemente tardía",
                "guid": "N8wwziKnwIdCu1cqb_y5oA",
                "children": []
              },
              {
                "id": "36",
                "parent": "33",
                "text": "◊ <5% mieloblastos",
                "guid": "PvIKMh9HU01bb2E6eejSxw",
                "children": []
              },
              {
                "id": "37",
                "parent": "33",
                "text": "◊ ★ Ausencia de displasia significativa (disgranulopoyesis)",
                "guid": "bH8A0mLs4wQRpHHpGBOnwA",
                "children": []
              },
              {
                "id": "38",
                "parent": "33",
                "text": "◊ Fibrosis reticulínica: Normal o mínima (≤ Grado 1)",
                "guid": "ZlHZsj6zOldcvJfkBVYS2w",
                "children": []
              },
              {
                "id": "39",
                "parent": "33",
                "text": "◊ Maduración eritroide normoblástica",
                "guid": "EyJ9BWkE6flLFzMuUaC4Sw",
                "children": []
              },
              {
                "id": "40",
                "parent": "33",
                "text": "◊ Megacariocitos: Número normal/ligeramente aumentado, morfología normal",
                "guid": "HKNA7RNXva4BsP72CDLeIg",
                "children": []
              }
            ]
          },
          {
            "id": "41",
            "parent": "1",
            "text": "› Morfología y\nFunción Neutrófilos",
            "guid": "Zcka3yRclG5FpLyaVr2dnw",
            "children": [
              {
                "id": "42",
                "parent": "41",
                "text": "◊ Granulaciones tóxicas, cuerpos de Döhle (posibles, no específicos, sugieren activación)",
                "guid": "CvJL9gUp5RZT9XegQr58xQ",
                "children": []
              },
              {
                "id": "43",
                "parent": "41",
                "text": "◊ Morfología puede ser normal",
                "guid": "J9GlnRawzsoyuzZlZsOvzw",
                "children": []
              },
              {
                "id": "44",
                "parent": "41",
                "text": "◊ Función: Reportes inconsistentes\n(actividad bactericida ↑ vs. ↓)",
                "guid": "NfgiGA4ql59grIKWInci6g",
                "children": []
              },
              {
                "id": "45",
                "parent": "41",
                "text": "◊ Posible propensión a infecciones\n(causa de muerte subestimada)",
                "guid": "cRd6o3JQ9H86isqqV2lUVg",
                "children": []
              }
            ]
          },
          {
            "id": "46",
            "parent": "1",
            "text": "› Criterios Diagnósticos (Ver Categoría Clasificaciones Diagnósticas)",
            "guid": "MQQu1hdHYo9cv2cxRCar2w",
            "children": []
          },
          {
            "id": "47",
            "parent": "1",
            "text": "› Diagnóstico\nDiferencial",
            "guid": "AExMiCfWml8Vx2QnHO-NdQ",
            "children": [
              {
                "id": "48",
                "parent": "47",
                "text": "◊ Reacción leucemoide (difícil distinción, buscar clonalidad/mutación **CSF3R**)",
                "guid": "Oy5YDRd4Yx0lImuYIPdy7A",
                "children": []
              },
              {
                "id": "49",
                "parent": "47",
                "text": "◊ LMC (**BCR::ABL1+**, >% mielocitos, basofilia, eosinofilia, trombocitosis)",
                "guid": "O9T3jGrHKDJ3tRCMRsdDgg",
                "children": []
              },
              {
                "id": "50",
                "parent": "47",
                "text": "◊ LMC-N (forma rara LMC, **BCR::ABL p230**, e19/a2)",
                "guid": "b_ENSEuqiCwJhcBHF8Ky5Q",
                "children": []
              },
              {
                "id": "51",
                "parent": "47",
                "text": "◊ LMCa (≥10% precursores, ★ displasia marcada) ⇄",
                "guid": "YltW9jxA9qx-hmK0GFN5Dg",
                "children": []
              },
              {
                "id": "52",
                "parent": "47",
                "text": "◊ LMMC (monocitosis >10% y ≥0.5x10⁹/L, displasia)",
                "guid": "SmuOS18y5Uo6ypv4O4MI7w",
                "children": []
              },
              {
                "id": "53",
                "parent": "47",
                "text": "◊ Otras NMP (PV, TE, MFP - características moleculares/morfológicas distintivas)",
                "guid": "UYPZyXVVZqMS7F1FAogInw",
                "children": []
              },
              {
                "id": "54",
                "parent": "47",
                "text": "◊ Neoplasias Mieloides/Linfoides con eosinofilia y fusiones TK\n(**PDGFRA, PDGFRB, FGFR1, PCM1::JAK2**)",
                "guid": "DJzJMm-rxHZGrrR6DOkVug",
                "children": []
              },
              {
                "id": "55",
                "parent": "47",
                "text": "◊ Leucocitosis paraneoplásica (tumores sólidos productores G-CSF:\nurológicos, pulmón, mesotelio, tiroides, sarcomas)",
                "guid": "F4Je1Vx2GKEp2KMvUrC24g",
                "children": []
              }
            ]
          },
          {
            "id": "56",
            "parent": "1",
            "text": "› Asociaciones",
            "guid": "c-57v077DsdzqCnPL8NzSw",
            "children": [
              {
                "id": "57",
                "parent": "56",
                "text": "◊ Policitemia Vera (PV): Reportes anecdóticos, posible asociación con terapia citorreductora previa, datos limitados.",
                "guid": "OcI2-WtdOlt2irbNKbNEQQ",
                "children": []
              },
              {
                "id": "58",
                "parent": "56",
                "text": "◊ ★ Trastornos Células Plasmáticas (hasta 32%):\nMG-LNC / Gammopatía monoclonal asociada a LNC",
                "guid": "NwfChwAQdxVBdfcmGWMZfQ",
                "children": [
                  {
                    "id": "59",
                    "parent": "58",
                    "text": "• Tipos: Mieloma Múltiple (MM), MGUS, Plasmocitoma",
                    "guid": "PFFtwT_8WdoxtpKMBrz8DQ",
                    "children": []
                  },
                  {
                    "id": "60",
                    "parent": "58",
                    "text": "• Predominio cadena ligera Lambda",
                    "guid": "Hy8_JGyBLoRCQAT8cLMY7Q",
                    "children": []
                  },
                  {
                    "id": "61",
                    "parent": "58",
                    "text": "• ⇄ Hipótesis: Reactiva (G-CSF por células plasmáticas) vs. Dos clones independientes\n(presencia mutaciones mieloides específicas como **SETBP1**)",
                    "guid": "YdaVJ1UsYkFzOyGMbnNeWQ",
                    "children": []
                  },
                  {
                    "id": "62",
                    "parent": "58",
                    "text": "• Casos sin mutación **CSF3R** reportados.\nRespuesta a terapia anti-plasmocítica.",
                    "guid": "RNgmtznp1gd7XHQTXFqFjA",
                    "children": []
                  },
                  {
                    "id": "63",
                    "parent": "58",
                    "text": "• ★ Importancia: Requiere demostración clonalidad mieloide para diagnóstico LNC concomitante.\nNiveles G-CSF pueden ayudar a distinguir.",
                    "guid": "Fl_uqCU1F0MvCzxuCk5qZw",
                    "children": []
                  }
                ]
              },
              {
                "id": "64",
                "parent": "56",
                "text": "◊ Otras: Síndrome de Sweet, Anemia hemolítica autoinmune, LMC previa\n(reporte caso con clon **CSF3R** emergente post-**TKI**)",
                "guid": "dDAmCiKzZj06Ed2yLfJdBA",
                "children": []
              }
            ]
          },
          {
            "id": "65",
            "parent": "1",
            "text": "› Citogenética",
            "guid": "DhCgmDCclIBXpaFFRRhjHw",
            "children": [
              {
                "id": "66",
                "parent": "65",
                "text": "◊ Anormalidades clonales: ~1/3 al diagnóstico o evolución (series recientes: 4.8%-32.5%)",
                "guid": "MK0LlRkbmGxee3ydbP55Vg",
                "children": []
              },
              {
                "id": "67",
                "parent": "65",
                "text": "◊ Más frecuentes: **+8, +21, del(11q), del(20q)**",
                "guid": "WRfyRhAyDylzu3VjeEcxaw",
                "children": []
              },
              {
                "id": "68",
                "parent": "65",
                "text": "◊ Menos frecuentes: del(7q), nulisomía 17, tetraploidía 21, +7, +9, t(1;20), del(Y), del(6), add(5p), del(15), monosomía 2 (inespecíficas pero no aleatorias en neoplasias mieloides)",
                "guid": "fLM9rTX7el9o-kpYXonS1Q",
                "children": []
              },
              {
                "id": "69",
                "parent": "65",
                "text": "◊ Reporte reciente: Reordenamiento **KMT2A::DCP1B** (posible evento tardío)",
                "guid": "CyfcoFw1a-VM_TEuUAADVw",
                "children": []
              }
            ]
          },
          {
            "id": "70",
            "parent": "1",
            "text": "› Patogénesis\nMolecular",
            "guid": "Fh9B7EhZpUIsWojjLH8wlA",
            "children": [
              {
                "id": "71",
                "parent": "70",
                "text": "◊ ★ Mutaciones **CSF3R**\n(Receptor G-CSF, Cr 1p34.3)",
                "guid": "bY68hVtlxVI2zZr8Yb7ijw",
                "children": [
                  {
                    "id": "72",
                    "parent": "71",
                    "text": "• Descubrimiento clave: **Maxson et al. (2013)**",
                    "guid": "fhkrj3DfeK4PsT-TDCnMKA",
                    "children": []
                  },
                  {
                    "id": "73",
                    "parent": "71",
                    "text": "• Frecuencia: Muy alta en LNC (**>80%-100%**)",
                    "guid": "IXwNLmdW4NlRQi9HUikYww",
                    "children": []
                  },
                  {
                    "id": "74",
                    "parent": "71",
                    "text": "• Tipos principales:",
                    "guid": "AHJ5RS-9q-Q_J5IaWYpriw",
                    "children": [
                      {
                        "id": "75",
                        "parent": "74",
                        "text": "◊ ★ Mutaciones proximales a membrana: Más comunes (**T6181**, **T615A**). Mecanismo: Pérdida O-glicosilación → ↑Dimerización → Activación ligando-independiente vía **JAK2** (y **BTK**).\nSensibles a **Ruxolitinib (JAKi)**.",
                        "guid": "P--7DTLjB31R0Zz2PKL4uw",
                        "children": []
                      },
                      {
                        "id": "76",
                        "parent": "74",
                        "text": "◊ ★ Mutaciones de truncamiento (cola citoplasmática): (**D771fs, S783fs, Y752X, W791Z**). También en Neutropenia Congénita Severa (NCS). Mecanismo: Pérdida motivos regulación negativa → ↓Internalización/degradación → ↑Expresión superficie, ↑actividad **STAT5**.\nSensibles a **Dasatinib (SRCi)** in vitro.",
                        "guid": "aN6B3TrL508bLMuQdAZefQ",
                        "children": []
                      },
                      {
                        "id": "77",
                        "parent": "74",
                        "text": "◊ Mutaciones compuestas: Coexistencia proximal + truncamiento (~30%). Leucemia agresiva (ratones). ★ Resistencia in vitro a **JAKi** y **SRCi**.\nDependencia señalización **MAPK** (sensible a **Trametinib (MEKi)**).",
                        "guid": "FwFTNGgp_L5EBmHVLSCVIA",
                        "children": []
                      }
                    ]
                  },
                  {
                    "id": "78",
                    "parent": "71",
                    "text": "• Validación funcional: **CSF3R T6181** induce NMP tipo LNC en ratones (**Fleishman et al.**), sensible a **ruxolitinib**.\nOtras mutaciones activantes (**T640N, N579Y**) también descritas y sensibles a **ruxolitinib**.",
                    "guid": "MIOiAHBg6rhZn8W0HhJehQ",
                    "children": []
                  },
                  {
                    "id": "79",
                    "parent": "71",
                    "text": "• ★ Genotipo-Fenotipo: **CSF3R T6181** asociada a peor pronóstico (edad>, WBC>, Hb<, Plaquetas<, Cariotipo anormal, ↓OS).\nOtras variantes **CSF3R** requieren interpretación cautelosa (posibles SNPs germinales).",
                    "guid": "S8awChBtYLB_0UEVSd_bmg",
                    "children": []
                  }
                ]
              },
              {
                "id": "80",
                "parent": "70",
                "text": "◊ Mutaciones Adicionales Concurrentes\n(Complejidad genética alta)",
                "guid": "AUzZXw-CgKhWCafCIsjmjQ",
                "children": [
                  {
                    "id": "81",
                    "parent": "80",
                    "text": "• Reguladores epigenéticos: **ASXL1 (30-81%)** ★ (predictor independiente ↓OS, **Elliott et al.**), **SETBP1 (14-56%)**, **EZH2**.",
                    "guid": "dtlhgSdL1wl08f9Rd0vaxg",
                    "children": []
                  },
                  {
                    "id": "82",
                    "parent": "80",
                    "text": "• Factores de splicing: **SRSF2 (21-43.5%)**, **U2AF1**, **U2AF2**, **SF3B1**, **ZRSR2**.",
                    "guid": "VwmC7jQZkWtQ1kZSFvk9-w",
                    "children": []
                  },
                  {
                    "id": "83",
                    "parent": "80",
                    "text": "• Factores de transcripción: **CUX1, GATA2, RUNX1**.",
                    "guid": "ZvyY6CKn40hTnDa2T9saxQ",
                    "children": []
                  },
                  {
                    "id": "84",
                    "parent": "80",
                    "text": "• Genes de señalización: **CBL, NRAS, PTPN11, JAK2** (infrecuente, ¿PV enmascarada?).",
                    "guid": "XXPKl27JAkZD4XlDdHUdyw",
                    "children": []
                  },
                  {
                    "id": "85",
                    "parent": "80",
                    "text": "• Enzimas: **ETNK1**.",
                    "guid": "VvL_BQfn2xghlbLrB3ahBQ",
                    "children": []
                  },
                  {
                    "id": "86",
                    "parent": "80",
                    "text": "• Reguladores separación cromosómica: **STAG2**.",
                    "guid": "eEjF0Hs1eKAliP-LRA912w",
                    "children": []
                  },
                  {
                    "id": "87",
                    "parent": "80",
                    "text": "• Mutaciones asociadas a Hematopoyesis Clonal (CHIP): **TET2 (10-20%)**, **DNMT3A (5-20%)**. ¿CHIP como base para mutación **CSF3R**?",
                    "guid": "C6LZUCVaQKAN71F1DO-yrw",
                    "children": []
                  },
                  {
                    "id": "88",
                    "parent": "80",
                    "text": "• Co-ocurrencias frecuentes: **CSF3R/SETBP1**, **ASXL1/CSF3R**.",
                    "guid": "NNzBSGP4-TcvuJk9K7Yiyg",
                    "children": []
                  },
                  {
                    "id": "89",
                    "parent": "80",
                    "text": "• ★ Mutaciones de Alto Riesgo (**Carreño-Tarragona et al. 2023**): **CBL, CEBPA, EZH2, NRAS, TET2, U2AF1** (impacto adverso en OS en cohorte LNC/LMCa).\n⇄ No corrobora impacto adverso **ASXL1**.",
                    "guid": "C0TQQCSqmI4jAf2QYk5TLg",
                    "children": []
                  }
                ]
              },
              {
                "id": "90",
                "parent": "70",
                "text": "◊ Predisposición Genética y\nMutaciones Germinales",
                "guid": "WMQp-XPYQ-J5R5EqP8DC4Q",
                "children": [
                  {
                    "id": "91",
                    "parent": "90",
                    "text": "• Mutaciones germinales **CSF3R** causan Neutrofilia Crónica Hereditaria.",
                    "guid": "FoAnK0zjx-APm92nc_Pxwg",
                    "children": []
                  },
                  {
                    "id": "92",
                    "parent": "90",
                    "text": "• Casos familiares LNC descritos (**CSF3R T617N, T6181** germinal).",
                    "guid": "O6zKJ1N9VupoaQ-OEp_JLA",
                    "children": []
                  },
                  {
                    "id": "93",
                    "parent": "90",
                    "text": "• Variantes germinales **CSF3R** como alelos de riesgo para malignidades hematológicas (**P733T**).",
                    "guid": "W2UyAgn-wnkaFmoxU6330g",
                    "children": []
                  }
                ]
              },
              {
                "id": "94",
                "parent": "70",
                "text": "◊ Secuenciación\n(NGS, WES, RNA)",
                "guid": "BTQ7GT-fabwXvW2tENcUag",
                "children": [
                  {
                    "id": "95",
                    "parent": "94",
                    "text": "• Confirma alta complejidad mutacional (media 3.6 mut/paciente).",
                    "guid": "ZPmqXCWsvyIdxscZGdZrpQ",
                    "children": []
                  },
                  {
                    "id": "96",
                    "parent": "94",
                    "text": "• Patrones mutacionales similares a LMMC, distintos a CHIP/otras NMP crónicas.",
                    "guid": "CaW4WU1_YFZFjI5vFOqImg",
                    "children": []
                  },
                  {
                    "id": "97",
                    "parent": "94",
                    "text": "• ★ Sensibilidad a combinación **Ruxolitinib + Trametinib** en células con **CSF3R + NRAS**.",
                    "guid": "cin45GiOi_93ONvISu4i3Q",
                    "children": []
                  }
                ]
              },
              {
                "id": "98",
                "parent": "70",
                "text": "◊ Orden Mutacional y\nEvolución Clonal",
                "guid": "XGbP4nCAbPIKruW_cub3DQ",
                "children": [
                  {
                    "id": "99",
                    "parent": "98",
                    "text": "• Patrón de adquisición propuesto: Lineal vs. ramificado. Mutaciones tempranas (**EZH2, SETBP1, TET2, U2AF1, SF3B1**) vs. irregulares (**ASXL1, SRSF2, CSF3R, CBL, NRAS**).",
                    "guid": "PWQ00xpKw2Zm2ujPeRD--g",
                    "children": []
                  },
                  {
                    "id": "100",
                    "parent": "98",
                    "text": "• Evolución clonal en transformación blástica: ↑ VAF **CSF3R**, adquisición nuevas mutaciones (**KIT, GATA2**) o ↑ VAF (**RUNX1**), mutaciones **STAG2**, nuevas anomalías citogenéticas (**-5, -7, +21, del(12p)**).",
                    "guid": "bcgaUE9D-F0LsMgmSS1MUg",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "101",
            "parent": "1",
            "text": "› Pronóstico e\nHistoria Natural",
            "guid": "WUK61yXHMlcc20QkXnb18A",
            "children": [
              {
                "id": "102",
                "parent": "101",
                "text": "◊ ★ Supervivencia media (OS) global pobre: 15-31 meses (series históricas y recientes).",
                "guid": "ZWacFDSYsdJvTgpaSmBGcA",
                "children": []
              },
              {
                "id": "103",
                "parent": "101",
                "text": "◊ ★ Tasa de transformación leucémica (LMA o LLA): ~10-25%. Mediana tiempo a LMA: 15-21 meses.",
                "guid": "WkVw9A0U0XRkNrIVY-spTg",
                "children": []
              },
              {
                "id": "104",
                "parent": "101",
                "text": "◊ Progresión a PV o LMMC: Menos común.",
                "guid": "WpQxyinDQIR41bHoTL4qrw",
                "children": []
              },
              {
                "id": "105",
                "parent": "101",
                "text": "◊ Causas de muerte: Hemorragia (intracraneal), infecciones, progresión enfermedad, LMA/LLA, toxicidad tratamiento.",
                "guid": "ElHMhHAOjbAXrE2MbricZg",
                "children": []
              },
              {
                "id": "106",
                "parent": "101",
                "text": "◊ Fases (ICC): Crónica, Acelerada (Blastos 10-19%, empeoramiento clínico/citopenias), Blástica (Blastos ≥20%).",
                "guid": "YI76oyJbM0thn5NzHfMvdg",
                "children": []
              }
            ]
          },
          {
            "id": "107",
            "parent": "1",
            "text": "› Variables Pronósticas y\nEstratificación de Riesgo",
            "guid": "PKX2sUh6fEIXBC5wKm4RAQ",
            "children": [
              {
                "id": "108",
                "parent": "107",
                "text": "◊ Factores adversos históricos/clínicos: Leucocitos >50-60x10⁹/L, Plaquetas <160x10⁹/L.",
                "guid": "F750oCK09pZzm11TcQEvdw",
                "children": []
              },
              {
                "id": "109",
                "parent": "107",
                "text": "◊ Factores genéticos\nadversos:",
                "guid": "SHwo7RB2oXhPeCVnLeLFAQ",
                "children": [
                  {
                    "id": "110",
                    "parent": "109",
                    "text": "• ★ Mutación **ASXL1** (**Elliott et al. **, Modelo **Mayo Clinic**)",
                    "guid": "RQ9TSj7GL8J4QwtyH1TEPg",
                    "children": []
                  },
                  {
                    "id": "111",
                    "parent": "109",
                    "text": "• ★ Tipo mutación **CSF3R** (**T6181** peor pronóstico)",
                    "guid": "S9sBNlx5vYcDP-2MJm8zAA",
                    "children": []
                  },
                  {
                    "id": "112",
                    "parent": "109",
                    "text": "• ★ Mutaciones de Alto Riesgo (**Carreño-Tarragona et al. 2023**): **CBL, CEBPA, EZH2, NRAS, TET2, U2AF1**.",
                    "guid": "Bjz-DHwVn3RzLV2vGI7KkA",
                    "children": []
                  },
                  {
                    "id": "113",
                    "parent": "109",
                    "text": "• Mutación **SETBP1**: Pronóstico incierto, posible rol en transformación/resistencia.",
                    "guid": "bCQtJQrZqzwHR2b2TLMnyA",
                    "children": []
                  }
                ]
              },
              {
                "id": "114",
                "parent": "107",
                "text": "◊ ★ Modelo de Riesgo\n**Mayo Clinic (Szuber et al.\n2018)**",
                "guid": "LTTeh2jm-mlqplc-adrVOQ",
                "children": [
                  {
                    "id": "115",
                    "parent": "114",
                    "text": "• Variables: Plaquetas <160x10⁹/L (2 puntos), Leucocitos >60x10⁹/L (1 punto), Mutación **ASXL1** (1 punto).",
                    "guid": "MWF2qwGqha4USOY6SR_rSw",
                    "children": []
                  },
                  {
                    "id": "116",
                    "parent": "114",
                    "text": "• Categorías: Bajo Riesgo (0-1 puntos; OS \"no alcanzada\") vs. Alto Riesgo (2-4 puntos; OS ~22.4 meses).",
                    "guid": "JF98RAfkQ446IRrCbNulMQ",
                    "children": []
                  },
                  {
                    "id": "117",
                    "parent": "114",
                    "text": "• Implicación: Alto riesgo → Monitorización estrecha, consideración temprana TAPH.",
                    "guid": "GFrlBgmZQCoavmozXWo4UA",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "id": "118",
            "parent": "1",
            "text": "› Manejo (Ver Categoría\nManejo y Terapias)",
            "guid": "SF9v7BMBdaV8vvyOFDpxIg",
            "children": []
          }
        ]
      },
      {
        "id": "119",
        "parent": "0",
        "text": "- Leucemia Mieloide Crónica Atípica (LMCa)\n/ MDS/NMP con Neutrofilia (OMS)",
        "guid": "b3szLH_-6hs6qaQidbgxOA",
        "children": [
          {
            "id": "120",
            "parent": "119",
            "text": "› Definición",
            "guid": "fBSJjy3XAdIORvvIaDi2tA",
            "children": [
              {
                "id": "121",
                "parent": "120",
                "text": "◊ Trastorno solapado MDS/NMP, BCR::ABL1 negativo",
                "guid": "OLCtDhWOYr406958ZeWLlQ",
                "children": []
              },
              {
                "id": "122",
                "parent": "120",
                "text": "◊ ★ Neutrofilia displásica",
                "guid": "fnVdJx-SNbpPwGDOL9bT0w",
                "children": []
              },
              {
                "id": "123",
                "parent": "120",
                "text": "◊ ★ ≥10% Precursores mieloides circulantes",
                "guid": "ITy7aGQJRwl49r8eRZw3rA",
                "children": []
              }
            ]
          },
          {
            "id": "124",
            "parent": "119",
            "text": "› Epidemiología",
            "guid": "a-2KlzMX2eEyd9zeBEhvnQ",
            "children": [
              {
                "id": "125",
                "parent": "124",
                "text": "◊ Muy rara (Incidencia relativa 1-2 / 100 LMC BCR::ABL1+)",
                "guid": "PLEaC002RxFhsqftBRCJ9w",
                "children": []
              },
              {
                "id": "126",
                "parent": "124",
                "text": "◊ Edad media: 70-74 años",
                "guid": "YDe8tl5xpHsZSvsZT7Lv4g",
                "children": []
              },
              {
                "id": "127",
                "parent": "124",
                "text": "◊ Predominio masculino (~65%)",
                "guid": "XnCOllP0nztFayEbWoUYJg",
                "children": []
              }
            ]
          },
          {
            "id": "128",
            "parent": "119",
            "text": "› Características\nClínicas",
            "guid": "AcuhDVOyHONCvc7aOnxOGw",
            "children": [
              {
                "id": "129",
                "parent": "128",
                "text": "◊ Frecuente: ★ Esplenomegalia (40-67%), Síntomas anemia/trombocitopenia (sangrado mucocutáneo ~15%), Síntomas constitucionales.",
                "guid": "aUB_oneprVcgYdmxZ7XcyQ",
                "children": []
              },
              {
                "id": "130",
                "parent": "128",
                "text": "◊ Menos frecuente: Enfermedad extramedular, CID, lisis tumoral, IR aguda.",
                "guid": "FzvjEXAiOn8XjLCcOHieeg",
                "children": []
              },
              {
                "id": "131",
                "parent": "128",
                "text": "◊ Dependencia transfusional: Hasta 1/3 al inicio.",
                "guid": "VCuBiBCDb7t-FNYmQBkMHw",
                "children": []
              }
            ]
          },
          {
            "id": "132",
            "parent": "119",
            "text": "› Hallazgos de\nLaboratorio",
            "guid": "Q5tJnDCMswREYXu8AExjpw",
            "children": [
              {
                "id": "133",
                "parent": "132",
                "text": "◊ ★ Leucocitosis neutrofílica (WBC ≥13x10⁹/L)",
                "guid": "fcL6FSYUI6kFXO2eXfq2yw",
                "children": []
              },
              {
                "id": "134",
                "parent": "132",
                "text": "◊ ★ ≥10% Precursores mieloides circulantes (promielocitos, mielocitos, metamielocitos)",
                "guid": "BIXIJR6n6LctraauYvZWuw",
                "children": []
              },
              {
                "id": "135",
                "parent": "132",
                "text": "◊ ★ Displasia granulocítica marcada (hipo/hipersegmentación, cromatina anormal, hipogranulación)",
                "guid": "cpyH8nMYx8k9e27hdGgpAA",
                "children": []
              },
              {
                "id": "136",
                "parent": "132",
                "text": "◊ Ausencia de monocitosis (<10%), eosinofilia (<10% ICC), basofilia.",
                "guid": "RsrkrAA5Pbwu5HcbMAtkTg",
                "children": []
              },
              {
                "id": "137",
                "parent": "132",
                "text": "◊ Anemia (Hb media 8.3-11 g/dL)",
                "guid": "d-LrE09GUMwXwUEYDx7OJA",
                "children": []
              },
              {
                "id": "138",
                "parent": "132",
                "text": "◊ Trombocitopenia (variable, Plaquetas medias 150-332x10⁹/L)",
                "guid": "P2iLTC9N8bRHl2yeE5QM1A",
                "children": []
              },
              {
                "id": "139",
                "parent": "132",
                "text": "◊ LDH elevada (frecuente)",
                "guid": "P9Fhb0WsQsVTrRj0A2yrCw",
                "children": []
              }
            ]
          },
          {
            "id": "140",
            "parent": "119",
            "text": "› Morfología\nMédula Ósea",
            "guid": "djj1yRgOlLADuQ6yc_vv3w",
            "children": [
              {
                "id": "141",
                "parent": "140",
                "text": "◊ ★ Hipercelular",
                "guid": "PiK4WgkV_FBR9qaqQqiAfw",
                "children": []
              },
              {
                "id": "142",
                "parent": "140",
                "text": "◊ ★ Predominio granulocítico con displasia marcada (Ratio M:E >10:1)",
                "guid": "J73lB3-kTVglntc6Glps-g",
                "children": []
              },
              {
                "id": "143",
                "parent": "140",
                "text": "◊ Displasia eritroide y/o megacariocítica (>50%)",
                "guid": "cr0VIWMaRhwOwpX6OYf5zg",
                "children": []
              },
              {
                "id": "144",
                "parent": "140",
                "text": "◊ Dismegacariopoyesis común (formas pequeñas hipolobuladas, micromegacariocitos)",
                "guid": "Y1OD2D2nDRVpk14cWzZu6w",
                "children": []
              },
              {
                "id": "145",
                "parent": "140",
                "text": "◊ Fibrosis reticulínica variable",
                "guid": "DO1d4gFUnzRqVT0PTFXpLg",
                "children": []
              },
              {
                "id": "146",
                "parent": "140",
                "text": "◊ ★ Blasts <20% (sangre y MO)",
                "guid": "MKKQ6THsqa5f6fYCcHPyWA",
                "children": []
              }
            ]
          },
          {
            "id": "147",
            "parent": "119",
            "text": "› Criterios Diagnósticos (Ver Categoría\nClasificaciones Diagnósticas)",
            "guid": "d5jsczOXDvZz4J1kbdHiPA",
            "children": []
          }
        ]
      },
      {
        "id": "148",
        "parent": "0",
        "text": "› Evaluación Diagnóstica y\nDiagnóstico Diferencial",
        "guid": "",
        "children": []
      },
      {
        "id": "149",
        "parent": "0",
        "text": "◊ Evaluación: Examen sangre periférica y MO, Exclusión **BCR::ABL1**\n(PCR/citogenética), Citogenética/FISH (excluir reordenamientos\n**PDGFRA/B, FGFR1, PCM1::JAK2**, etc.), ★ NGS panel mieloide\n(identificar mutaciones soporte/accionables, estratificar riesgo), Tipaje\nHLA (si candidato TAPH).",
        "guid": "",
        "children": []
      },
      {
        "id": "150",
        "parent": "0",
        "text": "◊ Diagnóstico\nDiferencial:",
        "guid": "",
        "children": []
      },
      {
        "id": "151",
        "parent": "0",
        "text": "• LMC (**BCR::ABL1+**, sin\ndisplasia marcada, basofilia)",
        "guid": "",
        "children": []
      },
      {
        "id": "152",
        "parent": "0",
        "text": "• LMMC (monocitosis\n>10% y ≥0.5-1x10⁹/L)",
        "guid": "",
        "children": []
      },
      {
        "id": "153",
        "parent": "0",
        "text": "• Otros MDS/NMP",
        "guid": "",
        "children": []
      },
      {
        "id": "154",
        "parent": "0",
        "text": "• MFP prefibrótica (atipia\nmegacariocítica PMF,\nmutaciones\n**JAK2/CALR/MPL**)",
        "guid": "",
        "children": []
      },
      {
        "id": "155",
        "parent": "0",
        "text": "• LNC (<10% precursores, ★\nausencia displasia marcada) ⇄",
        "guid": "",
        "children": []
      },
      {
        "id": "156",
        "parent": "0",
        "text": "• ⇄ Debate LNC vs LMCa: Entidad única vs. separadas.\n**Carreño-Tarragona et al. (2023)**: Perfiles moleculares/outcomes\nsimilares → entidad única. **Tremblay et al. (2023)**: OS\nsignificativamente diferente → entidades separadas. Clasificaciones\n**OMS/ICC 2022** las mantienen separadas.",
        "guid": "",
        "children": []
      },
      {
        "id": "157",
        "parent": "0",
        "text": "›\nCaracterísticas\nGenéticas",
        "guid": "",
        "children": []
      },
      {
        "id": "158",
        "parent": "0",
        "text": "◊ Citogenética",
        "guid": "",
        "children": []
      },
      {
        "id": "159",
        "parent": "0",
        "text": "• Anormalidades clonales: 15-40% (hasta\n82% en algunas series). Tasas más bajas en\nseries recientes (6-37%).",
        "guid": "",
        "children": []
      },
      {
        "id": "160",
        "parent": "0",
        "text": "• Más comunes: **+8,\n-7/del(7q), i(17q), del(20q)**",
        "guid": "",
        "children": []
      },
      {
        "id": "161",
        "parent": "0",
        "text": "• Cariotipos complejos:\nRaros (~5-10%)",
        "guid": "",
        "children": []
      },
      {
        "id": "162",
        "parent": "0",
        "text": "• Evolución: Nuevas anomalías\nen transformación a LMA\n(frecuente **i(17q)**).",
        "guid": "",
        "children": []
      },
      {
        "id": "163",
        "parent": "0",
        "text": "◊ Mutaciones y\nArquitectura Clonal",
        "guid": "",
        "children": []
      },
      {
        "id": "164",
        "parent": "0",
        "text": "• ★ Paisaje molecular complejo y\nheterogéneo: 100% pacientes mutados,\nmedia 3-4 mutaciones/paciente.",
        "guid": "",
        "children": []
      },
      {
        "id": "165",
        "parent": "0",
        "text": "• ★ Mutaciones más frecuentes: **ASXL1\n(43-92%)**, **SETBP1 (30-58%)**, **SRSF2\n(40-68%)**, **TET2 (13-35%)**, **EZH2 (8-32%)**.",
        "guid": "",
        "children": []
      },
      {
        "id": "166",
        "parent": "0",
        "text": "• Otras mutaciones\nrecurrentes (<10-20%):",
        "guid": "",
        "children": []
      },
      {
        "id": "167",
        "parent": "0",
        "text": "◊ Señalización: **CSF3R\n(3-24%)**, **NRAS/KRAS\n(10-33%)**, **CBL, JAK2**.",
        "guid": "",
        "children": []
      },
      {
        "id": "168",
        "parent": "0",
        "text": "◊ Metabólicas:\n**ETNK1 (7-16%)**.",
        "guid": "",
        "children": []
      },
      {
        "id": "169",
        "parent": "0",
        "text": "◊ Factores transcripción:\n**GATA2, RUNX1**.",
        "guid": "",
        "children": []
      },
      {
        "id": "170",
        "parent": "0",
        "text": "◊ Splicing: **U2AF1,\nSF3B1, ZRSR2**.",
        "guid": "",
        "children": []
      },
      {
        "id": "171",
        "parent": "0",
        "text": "◊ Regulación epigenética:\n**DNMT3A, IDH1/2**.",
        "guid": "",
        "children": []
      },
      {
        "id": "172",
        "parent": "0",
        "text": "◊ Otras: **CCND2** (rara, posible\nmarcador agresividad).",
        "guid": "",
        "children": []
      },
      {
        "id": "173",
        "parent": "0",
        "text": "• ★ Mutaciones de Soporte Diagnóstico: **SETBP1**\ny/o **ETNK1** (OMS); **ASXL1** y **SETBP1** (ICC)\nen ausencia de drivers NMP.",
        "guid": "",
        "children": []
      },
      {
        "id": "174",
        "parent": "0",
        "text": "• ★ Enriquecimiento vs LNC: **EZH2,\nTET2** más frecuentes en LMCa;\n**CSF3R** más frecuente en LNC.",
        "guid": "",
        "children": []
      },
      {
        "id": "175",
        "parent": "0",
        "text": "• ★ Mutaciones clave\ny asociaciones:",
        "guid": "",
        "children": []
      },
      {
        "id": "176",
        "parent": "0",
        "text": "◊ **SETBP1**: Inhibición **PP2A**. Asociación\nfuerte con **ASXL1, CBL**. Exclusión mutua con\n**JAK2, TET2**. Posible fenotipo adverso (WBC>,\nHb<, Plaquetas<, ↓OS).",
        "guid": "",
        "children": []
      },
      {
        "id": "177",
        "parent": "0",
        "text": "◊ **ETNK1**: ↓ Actividad enzimática → ↑ ROS,\ninestabilidad genómica. Evento temprano. Potencial\ndiana terapéutica (fosfoetanolamina).",
        "guid": "",
        "children": []
      },
      {
        "id": "178",
        "parent": "0",
        "text": "◊ **NRAS/KRAS**: Activación vía\nRAF-MEK-ERK. ★ Potencialmente tratables\ncon inhibidores MEK (**Trametinib**).",
        "guid": "",
        "children": []
      },
      {
        "id": "179",
        "parent": "0",
        "text": "• Perfil Expresión Génica: Diferencias vs LMMC. Clusters\ntranscripcionales asociados a pronóstico/características\nclínicas. Firma 3 genes (**DNPH1, GFI1B, PARP1**)\npredice mal pronóstico.",
        "guid": "",
        "children": []
      },
      {
        "id": "180",
        "parent": "0",
        "text": "• Co-mutaciones frecuentes:\n**SETBP1/ASXL1**, **SETBP1/CBL**,\n**SETBP1/CSF3R**, **ASXL1/CSF3R**,\n**SETBP1/U2AF1**, **EZH2/TET2**.",
        "guid": "",
        "children": []
      },
      {
        "id": "181",
        "parent": "0",
        "text": "• Orden Mutacional: Complejo. **ASXL1** a menudo\nancestral. **SETBP1** codominante/secundario a\n**ASXL1**. **ETNK1** puede preceder a **ASXL1**. VAFs\nsugieren **SETBP1, SRSF2, TET2, GATA2** como eventos\ntempranos en algunas series.",
        "guid": "",
        "children": []
      },
      {
        "id": "182",
        "parent": "0",
        "text": "• Transformación a LMA: Adquisición de\nnuevas mutaciones (señalización: **NRAS,\nKRAS, NF1, PTPN11**; **FLT3-ITD, ASXL1,\nCEBPA, ETV6**).",
        "guid": "",
        "children": []
      },
      {
        "id": "183",
        "parent": "0",
        "text": "› Pronóstico y\nEstratificación de\nRiesgo",
        "guid": "",
        "children": []
      },
      {
        "id": "184",
        "parent": "0",
        "text": "◊ ★ Pronóstico global pobre: OS media 12-20\nmeses. Peor que LNC y otras MDS/NMP.",
        "guid": "",
        "children": []
      },
      {
        "id": "185",
        "parent": "0",
        "text": "◊ ★ Alta tasa de transformación a LMA:\nHasta 40% en 12-18 meses.",
        "guid": "",
        "children": []
      },
      {
        "id": "186",
        "parent": "0",
        "text": "◊ Factores de riesgo para LMA: Organomegalia,\nmonocitosis, blastos MO >5%, diseritropoyesis,\ndependencia transfusional.",
        "guid": "",
        "children": []
      },
      {
        "id": "187",
        "parent": "0",
        "text": "◊ Estratificación de Riesgo: ★ Sin\nconsenso. Modelos integran factores\nclínicos y moleculares.",
        "guid": "",
        "children": []
      },
      {
        "id": "188",
        "parent": "0",
        "text": "• Factores clínicos adversos: Edad avanzada\n(>65-67 años), Anemia severa (Hb <10 g/dL),\nLeucocitosis alta (WBC >50x10⁹/L),\nTrombocitopenia, ↑% Blastos MO, ↑ LDH.",
        "guid": "",
        "children": []
      },
      {
        "id": "189",
        "parent": "0",
        "text": "• ★ Modelo **Onida et al. (2002)**\n(clínico): Edad>65, Hb≤10, WBC>50 →\nBajo (0-1) vs Alto (2-3) riesgo.",
        "guid": "",
        "children": []
      },
      {
        "id": "190",
        "parent": "0",
        "text": "• ★ Modelo **Montalban-Bravo et al.\n(2021)** (clínico, nomograma): Edad,\nPlaquetas, %Blastos MO, LDH.",
        "guid": "",
        "children": []
      },
      {
        "id": "191",
        "parent": "0",
        "text": "• ★ Modelo **Mayo Clinic (Patnaik et al. 2017)** (clínico-molecular):\nEdad >67 (1 pt), Hb <10 (1 pt), Mutación **TET2** (1 pt) → Bajo (0-1)\nvs Alto (≥2) riesgo (OS 18 vs 7 meses).",
        "guid": "",
        "children": []
      },
      {
        "id": "192",
        "parent": "0",
        "text": "• ★ Mutaciones con impacto\npronóstico (variable según estudios):",
        "guid": "",
        "children": []
      },
      {
        "id": "193",
        "parent": "0",
        "text": "◊ Adverso: **RUNX1, CUX1, NRAS**, posiblemente\n**SETBP1**. Mutaciones \"Alto Riesgo\"\n(**Carreño-Tarragona et al. 2023**, cohorte LNC/LMCa):\n**CBL, CEBPA, EZH2, NRAS, TET2, U2AF1**.",
        "guid": "",
        "children": []
      },
      {
        "id": "194",
        "parent": "0",
        "text": "◊ Favorable: **SRSF2**, posiblemente\n**SETBP1** (contradictorio).",
        "guid": "",
        "children": []
      },
      {
        "id": "195",
        "parent": "0",
        "text": "◊ **ASXL1**: Tan prevalente que su\nvalor pronóstico es limitado en\nalgunas series LMCa.",
        "guid": "",
        "children": []
      },
      {
        "id": "196",
        "parent": "0",
        "text": "• ★ TAPH Alogénico: Factor pronóstico favorable\nindependiente en múltiples análisis (↑OS).",
        "guid": "",
        "children": []
      },
      {
        "id": "197",
        "parent": "0",
        "text": "› Manejo (Ver Categoría\nManejo y Terapias)",
        "guid": "",
        "children": []
      },
      {
        "id": "198",
        "parent": "0",
        "text": "- Comparación y\nDistinciones LNC vs LMCa\n⇄",
        "guid": "",
        "children": []
      },
      {
        "id": "199",
        "parent": "0",
        "text": "› Similitudes",
        "guid": "",
        "children": []
      },
      {
        "id": "200",
        "parent": "0",
        "text": "◊ Neoplasias mieloides raras,\nneutrofílicas, BCR::ABL1 negativas",
        "guid": "",
        "children": []
      },
      {
        "id": "201",
        "parent": "0",
        "text": "◊ Clínica: Frecuente\nhepatoesplenomegalia, riesgo\ntransformación leucémica y\nmortalidad alta.",
        "guid": "",
        "children": []
      },
      {
        "id": "202",
        "parent": "0",
        "text": "◊ Genética: Complejidad,\nsolapamiento mutacional\n(**ASXL1, SETBP1, SRSF2**, etc.)",
        "guid": "",
        "children": []
      },
      {
        "id": "203",
        "parent": "0",
        "text": "◊ Terapéutica: Respuesta variable,\nTAPH única opción curativa.",
        "guid": "",
        "children": []
      },
      {
        "id": "204",
        "parent": "0",
        "text": "› Diferencias Clave",
        "guid": "",
        "children": []
      },
      {
        "id": "205",
        "parent": "0",
        "text": "◊ ★ Morfología: LNC (Neutrófilos maduros, <10%\nprecursores, SIN displasia) vs LMCa (≥10%\nprecursores, CON displasia marcada).",
        "guid": "",
        "children": []
      },
      {
        "id": "206",
        "parent": "0",
        "text": "◊ ★ Genética Driver: LNC (Mutación **CSF3R** >80%, esp. **T6181**)\nvs LMCa (Mutaciones **CSF3R** <25%, enriquecida en **SETBP1,\nASXL1, SRSF2, TET2, EZH2, ETNK1**).",
        "guid": "",
        "children": []
      },
      {
        "id": "207",
        "parent": "0",
        "text": "◊ ★ Pronóstico: LMCa generalmente peor OS\nque LNC (según **Tremblay 2023**).",
        "guid": "",
        "children": []
      },
      {
        "id": "208",
        "parent": "0",
        "text": "◊ ★ Clasificación: LNC (NMP)\nvs LMCa (MDS/NMP).",
        "guid": "",
        "children": []
      },
      {
        "id": "209",
        "parent": "0",
        "text": "- Manejo y Terapias (Enfoque Global\ny Específico por Entidad)",
        "guid": "",
        "children": []
      },
      {
        "id": "210",
        "parent": "0",
        "text": "› Principios Generales",
        "guid": "",
        "children": []
      },
      {
        "id": "211",
        "parent": "0",
        "text": "◊ ★ Sin estándar de\ncuidado actual (**2024**).",
        "guid": "",
        "children": []
      },
      {
        "id": "212",
        "parent": "0",
        "text": "◊ Manejo individualizado:\nBasado en riesgo, síntomas,\nelegibilidad TAPH.",
        "guid": "",
        "children": []
      },
      {
        "id": "213",
        "parent": "0",
        "text": "◊ ★ TAPH Alogénico: Única opción\npotencialmente curativa.",
        "guid": "",
        "children": []
      },
      {
        "id": "214",
        "parent": "0",
        "text": "◊ Priorizar\nensayos\nclínicos.",
        "guid": "",
        "children": []
      },
      {
        "id": "215",
        "parent": "0",
        "text": "◊ Necesidad urgente de terapias\nmodificadoras de enfermedad.",
        "guid": "",
        "children": []
      },
      {
        "id": "216",
        "parent": "0",
        "text": "› Manejo Específico LNC\n(Algoritmo Figura 2)",
        "guid": "",
        "children": []
      },
      {
        "id": "217",
        "parent": "0",
        "text": "◊ Evaluación inicial: Diagnóstico, Panel\nmutacional (NGS), Estratificación Riesgo\n(**Mayo Clinic**, mutaciones alto riesgo).",
        "guid": "",
        "children": []
      },
      {
        "id": "218",
        "parent": "0",
        "text": "◊ Evaluación\nelegibilidad TAPH.",
        "guid": "",
        "children": []
      },
      {
        "id": "219",
        "parent": "0",
        "text": "◊ Indicaciones de tratamiento: Leucocitosis no\ncontrolada (>25-30x10⁹/L), Síntomas (incl.\nesplenomegalia sintomática).",
        "guid": "",
        "children": []
      },
      {
        "id": "220",
        "parent": "0",
        "text": "◊ Pacientes\nElegibles para\nTAPH:",
        "guid": "",
        "children": []
      },
      {
        "id": "221",
        "parent": "0",
        "text": "• ★ Considerar TAPH\n(temprano si alto riesgo).",
        "guid": "",
        "children": []
      },
      {
        "id": "222",
        "parent": "0",
        "text": "• Terapia puente (si necesaria):\nHidroxiurea (HU), Inhibidor JAK (iJAK -\n**Ruxolitinib, Fedratinib**).",
        "guid": "",
        "children": []
      },
      {
        "id": "223",
        "parent": "0",
        "text": "◊ Pacientes No Elegibles para\nTAPH / Post-Fallo TAPH:",
        "guid": "",
        "children": []
      },
      {
        "id": "224",
        "parent": "0",
        "text": "• 1. Ensayo\nClínico\n(preferido).",
        "guid": "",
        "children": []
      },
      {
        "id": "225",
        "parent": "0",
        "text": "• 2. Observación activa (si\nasintomático, bajo riesgo).",
        "guid": "",
        "children": []
      },
      {
        "id": "226",
        "parent": "0",
        "text": "• 3. Terapia\nfarmacológica:",
        "guid": "",
        "children": []
      },
      {
        "id": "227",
        "parent": "0",
        "text": "◊ Basada en mutación (si posible): **CSF3R**\nproximal → iJAK. **CSF3R** truncada →\n¿**Dasatinib**? (datos in vitro) / HU.",
        "guid": "",
        "children": []
      },
      {
        "id": "228",
        "parent": "0",
        "text": "◊ Agentes convencionales (1ª\nlínea estándar: HU;\nAlternativa: IFN-α, iJAK).",
        "guid": "",
        "children": []
      },
      {
        "id": "229",
        "parent": "0",
        "text": "◊ Terapias de rescate (si\nfallo/intolerancia):\nSecuenciar HU, IFN, iJAK.",
        "guid": "",
        "children": []
      },
      {
        "id": "230",
        "parent": "0",
        "text": "› Manejo Específico LMCa\n(Algoritmo Figura 4)",
        "guid": "",
        "children": []
      },
      {
        "id": "231",
        "parent": "0",
        "text": "◊ Evaluación inicial: Diagnóstico, Panel mutacional\n(NGS), Estratificación Riesgo (**Mayo Clinic**, otros\nfactores clínicos/moleculares).",
        "guid": "",
        "children": []
      },
      {
        "id": "232",
        "parent": "0",
        "text": "◊ Evaluación\nelegibilidad TAPH.",
        "guid": "",
        "children": []
      },
      {
        "id": "233",
        "parent": "0",
        "text": "◊ Indicaciones de tratamiento:\nSimilar a LNC (leucocitosis,\nsíntomas), manejo citopenias.",
        "guid": "",
        "children": []
      },
      {
        "id": "234",
        "parent": "0",
        "text": "◊ Pacientes\nElegibles para\nTAPH:",
        "guid": "",
        "children": []
      },
      {
        "id": "235",
        "parent": "0",
        "text": "• ★ Considerar TAPH (preferiblemente\ntemprano/al diagnóstico).",
        "guid": "",
        "children": []
      },
      {
        "id": "236",
        "parent": "0",
        "text": "• Terapia puente (si necesaria): HU, IFN, iJAK,\nAgentes Hipometilantes (HMA - **Azacitidina,\nDecitabina**), QT inducción (si agresivo).",
        "guid": "",
        "children": []
      },
      {
        "id": "237",
        "parent": "0",
        "text": "◊ Pacientes No Elegibles para\nTAPH / Post-Fallo TAPH:",
        "guid": "",
        "children": []
      },
      {
        "id": "238",
        "parent": "0",
        "text": "• 1. Ensayo\nClínico\n(preferido).",
        "guid": "",
        "children": []
      },
      {
        "id": "239",
        "parent": "0",
        "text": "• 2. Observación activa (si\nasintomático, bajo riesgo).",
        "guid": "",
        "children": []
      },
      {
        "id": "240",
        "parent": "0",
        "text": "• 3. Terapia\nfarmacológica:",
        "guid": "",
        "children": []
      },
      {
        "id": "241",
        "parent": "0",
        "text": "◊ Identificar mutaciones potencialmente tratables: **JAK2/CSF3R**\nproximal → iJAK. **CSF3R** truncada → ¿**Dasatinib**?. **NRAS/KRAS**\n→ Inhibidor MEK (**Trametinib**, datos limitados). ★ Uso preferente en\nensayo clínico o valorar off-label.",
        "guid": "",
        "children": []
      },
      {
        "id": "242",
        "parent": "0",
        "text": "◊ Si no hay mutaciones tratables / Fallo\nterapia dirigida: Agentes convencionales\n(HU, IFN, HMA) o iJAK (especialmente si\nsíntomas/proliferación alta).",
        "guid": "",
        "children": []
      },
      {
        "id": "243",
        "parent": "0",
        "text": "◊ Manejo citopenias:\nESA, transfusiones.",
        "guid": "",
        "children": []
      },
      {
        "id": "244",
        "parent": "0",
        "text": "◊ Terapias de rescate:\nSecuenciar opciones\ndisponibles (HU, IFN, HMA,\niJAK).",
        "guid": "",
        "children": []
      },
      {
        "id": "245",
        "parent": "0",
        "text": "› Terapias Comunes y\nConsideraciones",
        "guid": "",
        "children": []
      },
      {
        "id": "246",
        "parent": "0",
        "text": "◊ ★ Hidroxiurea (HU): Agente citorreductor\nmás usado en ambas, respuesta inicial\nfrecuente pero transitoria.",
        "guid": "",
        "children": []
      },
      {
        "id": "247",
        "parent": "0",
        "text": "◊ ★ Interferón-alfa (IFN-α): Potencial\nremisiones duraderas (más evidencia en\nLNC), toxicidad limita uso.",
        "guid": "",
        "children": []
      },
      {
        "id": "248",
        "parent": "0",
        "text": "◊ ★ Inhibidores JAK (iJAK - **Ruxolitinib, Fedratinib**): Respuesta mejor en LNC\n(especialmente **CSF3R** mutada) que en LMCa. **Fedratinib** con perfil\ninhibición más amplio (potencial ventaja en MDS/NMP). Papel en resistencia /\nmutaciones coexistentes aún en estudio.",
        "guid": "",
        "children": []
      },
      {
        "id": "249",
        "parent": "0",
        "text": "◊ ★ Agentes Hipometilantes (HMA - **Azacitidina, Decitabina**): Rol\nmás establecido en MDS/CMML. Uso off-label en LMCa, eficacia\ninconsistente/limitada en estudios recientes.",
        "guid": "",
        "children": []
      },
      {
        "id": "250",
        "parent": "0",
        "text": "◊ Quimioterapia Inducción (tipo LMA):\nGeneralmente ineficaz/tóxica en fase crónica,\nrol limitado como puente a TAPH en casos\nagresivos/transformados.",
        "guid": "",
        "children": []
      },
      {
        "id": "251",
        "parent": "0",
        "text": "◊ Terapias Dirigidas (más allá de iJAK):\n**Dasatinib** (SRCi), **Trametinib** (MEKi) →\nRacional molecular, datos clínicos muy\nlimitados/anecdóticos. Necesitan validación.",
        "guid": "",
        "children": []
      },
      {
        "id": "252",
        "parent": "0",
        "text": "◊ ★ TAPH Alogénico: ★ ÚNICA CURA. Selección pacientes,\ntiming óptimo (temprano vs. diferido), rol terapia puente,\nregímenes acondicionamiento, monitorización post-TAPH →\nÁreas de investigación activa.",
        "guid": "",
        "children": []
      },
      {
        "id": "253",
        "parent": "0",
        "text": "- Clasificaciones Diagnósticas (**OMS 2022** /\n**ICC 2022**) (Basado en Tabla 1) ⇄",
        "guid": "",
        "children": []
      },
      {
        "id": "254",
        "parent": "0",
        "text": "› Leucemia\nNeutrofílica Crónica\n(LNC)",
        "guid": "",
        "children": []
      },
      {
        "id": "255",
        "parent": "0",
        "text": "◊ Criterios\n**OMS 2022**:",
        "guid": "",
        "children": []
      },
      {
        "id": "256",
        "parent": "0",
        "text": "• Leucocitosis\n≥25x10⁹/L",
        "guid": "",
        "children": []
      },
      {
        "id": "257",
        "parent": "0",
        "text": "• Segmentados+Bandas ≥80% WBC,\nPrecursores <10% WBC",
        "guid": "",
        "children": []
      },
      {
        "id": "258",
        "parent": "0",
        "text": "• Monocitos <10% WBC,\nsin criterios LMMC",
        "guid": "",
        "children": []
      },
      {
        "id": "259",
        "parent": "0",
        "text": "• Sin\ndisgranulopoyesis",
        "guid": "",
        "children": []
      },
      {
        "id": "260",
        "parent": "0",
        "text": "• MO: Hipercelular, ↑granulocitos\nmaduración normal, <5% blastos",
        "guid": "",
        "children": []
      },
      {
        "id": "261",
        "parent": "0",
        "text": "• Exclusión: LMC, PV, TE, MFP,\nReordenamientos (**PDGFRA/B,\nFGFR1, PCM1::JAK2**)",
        "guid": "",
        "children": []
      },
      {
        "id": "262",
        "parent": "0",
        "text": "• Requerido: ★ Mutación **CSF3R** activante (T6181 u otra) O (si\nnegativa): Neutrofilia persistente (≥3m) + Esplenomegalia + Exclusión\ncausas reactivas (incl. neoplasia células plasmáticas con prueba\nclonalidad mieloide si presente)",
        "guid": "",
        "children": []
      },
      {
        "id": "263",
        "parent": "0",
        "text": "◊ Criterios\n**ICC 2022**:",
        "guid": "",
        "children": []
      },
      {
        "id": "264",
        "parent": "0",
        "text": "• Leucocitosis ★ ≥13x10⁹/L si **CSF3R**\nmutado, ≥25x10⁹/L si no mutado.",
        "guid": "",
        "children": []
      },
      {
        "id": "265",
        "parent": "0",
        "text": "• Resto criterios sangre periférica y MO\nsimilares a OMS, pero Blasts <20%\n(10-19% = fase acelerada).",
        "guid": "",
        "children": []
      },
      {
        "id": "266",
        "parent": "0",
        "text": "• Exclusiones\nsimilares a OMS.",
        "guid": "",
        "children": []
      },
      {
        "id": "267",
        "parent": "0",
        "text": "• Requerimiento mutación\n**CSF3R** / Criterios\nalternativos: Idéntico a OMS.",
        "guid": "",
        "children": []
      },
      {
        "id": "268",
        "parent": "0",
        "text": "› Leucemia Mieloide Crónica\nAtípica (LMCa) / MDS/NMP con\nNeutrofilia (OMS)",
        "guid": "",
        "children": []
      },
      {
        "id": "269",
        "parent": "0",
        "text": "◊ Criterios **OMS 2022**\n(MDS/NMP con Neutrofilia):",
        "guid": "",
        "children": []
      },
      {
        "id": "270",
        "parent": "0",
        "text": "• Leucocitosis\n≥13x10⁹/L con\nneutrofilia",
        "guid": "",
        "children": []
      },
      {
        "id": "271",
        "parent": "0",
        "text": "• Precursores mieloides\ncirculantes ≥10% WBC",
        "guid": "",
        "children": []
      },
      {
        "id": "272",
        "parent": "0",
        "text": "• ★ Displasia neutrofílica",
        "guid": "",
        "children": []
      },
      {
        "id": "273",
        "parent": "0",
        "text": "• Monocitos\n<10% WBC",
        "guid": "",
        "children": []
      },
      {
        "id": "274",
        "parent": "0",
        "text": "• MO: Hipercelular, predominio\ngranulocítico y displasia (+/- otras\nlíneas). Blasts <20% (sangre y MO).",
        "guid": "",
        "children": []
      },
      {
        "id": "275",
        "parent": "0",
        "text": "• Exclusión: LMC, PV, TE, MFP, LMMC, ★ MDS/MPN-RS-T,\nReordenamientos (**PDGFRA/B, FGFR1, PCM1::JAK2**). Ausencia\nmutaciones **JAK2, MPL, CALR, CSF3R**.",
        "guid": "",
        "children": []
      },
      {
        "id": "276",
        "parent": "0",
        "text": "• Deseable documentar: ★ Mutación\n**SETBP1** y/o **ETNK1**.",
        "guid": "",
        "children": []
      },
      {
        "id": "277",
        "parent": "0",
        "text": "◊ Criterios **ICC\n2022** (LMCa):",
        "guid": "",
        "children": []
      },
      {
        "id": "278",
        "parent": "0",
        "text": "• Leucocitosis ≥13x10⁹/L con\nPrecursores mieloides ≥10% WBC.",
        "guid": "",
        "children": []
      },
      {
        "id": "279",
        "parent": "0",
        "text": "• ★ Citopenia(s) (umbral MDS).",
        "guid": "",
        "children": []
      },
      {
        "id": "280",
        "parent": "0",
        "text": "• Blasts <20%\n(sangre y MO).",
        "guid": "",
        "children": []
      },
      {
        "id": "281",
        "parent": "0",
        "text": "• ★ Disgranulopoyesis.",
        "guid": "",
        "children": []
      },
      {
        "id": "282",
        "parent": "0",
        "text": "• Monocitos <10% WBC.\nEosinófilos <10% WBC.",
        "guid": "",
        "children": []
      },
      {
        "id": "283",
        "parent": "0",
        "text": "• MO: Hipercelular,\nhiperplasia y displasia\ngranulocítica (+/- otras\nlíneas).",
        "guid": "",
        "children": []
      },
      {
        "id": "284",
        "parent": "0",
        "text": "• Exclusión: LMC, PV, TE, MFP,\nReordenamientos TK. Ausencia\nmutaciones **JAK2, MPL, CALR**.",
        "guid": "",
        "children": []
      },
      {
        "id": "285",
        "parent": "0",
        "text": "• Deseable documentar: ★ Mutación\n**ASXL1** y **SETBP1**.",
        "guid": "",
        "children": []
      }
    ]
  },
  "node_count": 286,
  "relations": [],
  "cross_references": [],
  "specialty": "Hematología",
  "folder": "- Entidades clínicas/Hematología",
  "filename": "Paper. Leucemia Neutrofílica Crónica y Leucemia Mieloide Cronica Atípica-2025-1",
  "id": "map_1432",
  "resolved_references": []
}